Filtered By:
Condition: Insomnia

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 877 results found since Jan 2013.

Does your child have narcolepsy?
Teens are a notoriously sleepy bunch. Left to their own devices, many will happily snooze into the early hours of the afternoon. About 28 percent of teens also report falling asleep in school at least once a week, according to a poll by the National Sleep Foundation. This can make it difficult for parents to know when a teenager’s love affair with sleep might be the sign of narcolepsy or another sleep disorder. While narcolepsy is a rare condition, affecting only about .05 percent of the U.S. population, it often goes undiagnosed. It is a condition that typically develops between ages 10 and 20. “Patients with narcolep...
Source: Thrive, Children's Hospital Boston - August 10, 2017 Category: Pediatrics Authors: Ellen Greenlaw Tags: Diseases & Conditions Center for Pediatric Sleep Disorders Dr. Kiran Maski insomnia Narcolepsy Source Type: news

Delayed Diagnosis, Range of Severity, and Multiple Sleep Comorbidities: A Clinical and Polysomnographic Analysis of 100 Patients of the Innsbruck Narcolepsy Cohort
Conclusion:This study is one of the largest monocentric polysomnographic studies to date of patients with narcolepsy and confirms the frequent comorbidity of narcolepsy with many other sleep disorders. Our study is the first to evaluate the percentage of patients with high frequency leg movements and excessive fragmentary myoclonus in narcolepsy and is the first to demonstrate EMG evidence of RBD in the MSLT. These findings add to the growing body of literature suggesting that motor instability is a key feature of narcolepsy.Citation:Frauscher B; Ehrmann L; Mitterling T; Gabelia D; Gschliesser V; Brandauer E; Poewe W; H&ou...
Source: Journal of Clinical Sleep Medicine : JCSM - August 15, 2013 Category: Sleep Medicine Source Type: research

Attention-Deficit/Hyperactivity Disorder (ADHD) Symptoms in Pediatric Narcolepsy: A Cross-Sectional Study
Conclusions:Pediatric patients with narcolepsy have high levels of treatment-resistant attention-deficit/hyperactivity disorder (ADHD) symptoms. The optimal treatment for ADHD symptoms in these patients warrants further evaluation in longitudinal intervention studies.Citation:Lecendreux M, Lavault S, Lopez R, Inocente CO, Konofal E, Cortese S, Franco P, Arnulf I, Dauvilliers Y. Attention-deficit/hyperactivity disorder (adhd) symptoms in pediatric narcolepsy: a cross-sectional study. SLEEP 2015;38(8):1285–1295.
Source: Sleep - August 1, 2015 Category: Sleep Medicine Source Type: research

Patients' journeys to a narcolepsy diagnosis: a physician survey and retrospective chart review.
This report describes results from an online, quantitative, company-sponsored survey in which physicians provided information from the charts of their patients with narcolepsy. Neurologists, pulmonologists, psychiatrists, and other specialists who were board certified in sleep medicine; had 2 to 30 years of clinical experience; and treated ≥ 5 narcolepsy patients per month were invited to complete ≤ 6 surveys using charts of patients who were treated for narcolepsy in the last 6 months. Data from 252 patients were collected from 77 physicians. Patients were predominantly male (55%), white (67%), and had a median age of...
Source: Postgraduate Medicine - November 28, 2014 Category: Internal Medicine Tags: Postgrad Med Source Type: research

Narcolepsy type 1 and hypersomnia associated with a psychiatric disorder show different slow wave activity dynamics.
In conclusion, narcolepsy type1 and hypersomnia associated with psychiatric disorder differ in the SWA dynamics. Narcoleptics presented with the altered dynamics of sleep homeostasis, whereas psychiatric hypersomniacs showed normal nocturnal sleep and normal sleep homeostasis. PMID: 28691719 [PubMed - in process]
Source: Acta Neurobiologiae Experimentalis - July 13, 2017 Category: Neurology Authors: Walacik-Ufnal E, Piotrowska AJ, Wołyńczyk-Gmaj D, Januszko P, Gmaj B, Ufnal M, Kabat M, Wojnar M Tags: Acta Neurobiol Exp (Wars) Source Type: research

Long-term efficacy of solriamfetol for excessive sleepiness in narcolepsy or obstructive sleep apnea
Conclusions: These results demonstrate long-term efficacy and safety of solriamfetol for EDS in narcolepsy or OSA.
Source: European Respiratory Journal - November 20, 2019 Category: Respiratory Medicine Authors: Pepin, J.-L., Schwab, R., Shapiro, C., Hedner, J., Ahmed, M., Foldvary-Schaefer, N., Strollo, P., Mayer, G., Sarmiento, K., Baladi, M., Chandler, P., Lee, L., Malhotra, A. Tags: Sleep and control of breathing Source Type: research

Pitolisant for treating patients with narcolepsy.
This article aims to review pitolisant.Areas covered: In this paper the chemical properties, mechanism of action, pharmacokinetics, clinical efficacy and safety of pitolisant was introduced, and the development course of drugs for treating narcolepsy is also briefly described. We performed a systematic review of the literature using PubMed and the following keywords were used: "pitolisant" and "narcolepsy", "cataplexy" and "excessive daytime sleepiness" and "histamine 3 receptor".Expert opinion: Pitolisant is a histamine 3 receptor antagonist/inverse agonist. It can activate histamine release in the brain and enhances wake...
Source: Pharmacological Reviews - January 14, 2020 Category: Drugs & Pharmacology Authors: Li S, Yang J Tags: Expert Rev Clin Pharmacol Source Type: research

Depressive feelings in children with narcolepsy
Conclusion: In our large cohort, high levels of depressive symptoms essentially expressed by fatigue affected 25% of children with narcolepsy. The girls older than 10years of age were especially vulnerable. The similar prevalence of depressive feelings in treated vs never-treated patients suggests a specific need for diagnosing and managing this symptom in young patients with narcolepsy.
Source: Sleep Medicine - January 9, 2014 Category: Sleep Medicine Authors: Clara Odilia Inocente, Marie-Paule Gustin, Sophie Lavault, Anne Guignard-Perret, Aude Raoux, Noemie Christol, Daniel Gerard, Yves Dauvilliers, Rubens Reimão, Flora Bat-Pitault, Jian-Sheng Lin, Isabelle Arnulf, Michel Lecendreux, Patricia Franco Tags: Original Articles Source Type: research

Cataplexy as a side effect of modafinil in a patient without narcolepsy
The objective of this article is to describe an unexpected side effect of the use of modafinil in a patient with incorrect diagnosis of narcolepsy.
Source: Sleep Science - November 6, 2014 Category: Sleep Medicine Source Type: research

Effect of Oral JZP-110 (ADX-N05) on Wakefulness and Sleepiness in Adults with Narcolepsy: A Phase 2b Study
Conclusions:At doses of 150–300 mg/day, JZP-110 was well tolerated and significantly improved the ability to stay awake and subjective symptoms of excessive sleepiness in adults with narcolepsy.Clinical Trials Registration:Clinicaltrials.gov identifier NCT01681121.Citation:Ruoff C, Swick TJ, Doekel R, Emsellem HA, Feldman NT, Rosenberg R, Bream G, Khayrallah MA, Lu Y, Black J. Effect of oral JZP-110 (ADX-N05) on wakefulness and sleepiness in adults with narcolepsy: a phase 2b study. SLEEP 2016;39(7):1379–1387.
Source: Sleep - July 1, 2016 Category: Sleep Medicine Source Type: research

Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy.
Authors: Yang J, Gao J Abstract Introduction: Narcolepsy is a chronic disabling condition, excessive daytime somnolence is the main symptoms of it. There is currently no cure for narcolepsy, and hence there is a great need for new treatment options. Solriamfetol is a new selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects. The purpose of this paper is to review solriamfetol. Areas covered: The chemical property, mechanism of action, pharmacokinetics, clinical efficacy, and safety of solriamfetol are introduced in this paper. Expert opinion: Solriamfetol can bind to dopamine a...
Source: Expert Review of Clinical Pharmacology - June 20, 2019 Category: Drugs & Pharmacology Tags: Expert Rev Clin Pharmacol Source Type: research

Pitolisant: A Review in Narcolepsy with or without Cataplexy
AbstractPitolisant (Wakix®), an orally available, first-in-class antagonist/inverse agonist of the histamine 3 receptor, is approved in the EU (as of March 2016) for the treatment of narcolepsy with or without cataplexy in adults and in the USA (as of August 2019) for the treatment of excessive daytime sleepiness (EDS) in adults with narcolepsy. Pitolisant was demonstrated to have minimal risk of abuse in preclinical and clinical studies, and is the only anti-narcoleptic drug not scheduled as a controlled substance in the USA. The totality of evidence from pivotal and supportive phase III trials suggests that pitolisant a...
Source: CNS Drugs - January 28, 2020 Category: Neurology Source Type: research

Real-life WAKE study in narcolepsy patients with cataplexy treated with pitolisant and unresponsive to previous treatments
CONCLUSIONS: In patients with type I narcolepsy who do not respond to or do not tolerate the available treatments, pitolisant can improve their clinical situation and reduce their medication consumption. Studies with a higher level of evidence are needed to confirm these results.PMID:36169322 | DOI:10.33588/rn.7507.2022090
Source: Revista de Neurologia - September 28, 2022 Category: Neurology Authors: R Del R ío-Villegas F J Mart ínez-Orozco O Romero-Santo Tom ás M Y ébenes-Cortés M G ómez-Barrera C Gaig-Ventura Source Type: research